...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: News out - Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb’s Immune Checkpoint Inhibitor OPDIV

acchhh,,the major insiders and the RVX Team probably cant agree on anything. We do see that there is a huge disconnect bewteen the CEOs vision and what actually takes place ,,almost as if he is not part of the inner circle anymore! Just an observation. And it might account for us sitting with our thumbs up our backsides for as many years! Just a thought! We will be made aware of the true history at some point!

Share
New Message
Please login to post a reply